Advent Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Advent Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,000	Closed	-$147K	–	348
2018 Q3	$147K	Buy	+5,000	New	+$194K	﹤0.01%	225
2017 Q4	–	Sell	-5,000	Closed	-$412K	–	323
2017 Q3	$412K	Sell	5,000 -13,750	-73%	-$1.09M	0.01%	206
2017 Q2	$1.76M	Buy	18,750 +13,750	+275%	+$841K	0.03%	171
2017 Q1	$318K	Buy	+5,000	New	+$304K	0.01%	201
2016 Q4	–	Sell	-5,000	Closed	-$176K	–	346
2016 Q3	$180K	Buy	+5,000	New	+$107K	﹤0.01%	418
2016 Q2	–	Sell	-13,900	Closed	-$267K	–	494
2016 Q1	$267K	Buy	+13,900	New	+$294K	﹤0.01%	349

Other funds holding CLVS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Advent Capital Management's CLVS Position: Q4 2018 in Review

Advent Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 5,000 shares — an estimated $147K sold.

Advent Capital Management first reported a position in CLVS in Q1 2016 and held it in 6 quarters. The position peaked at $1.76M in Q2 2017. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

Advent Capital Management reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
Advent Capital Management sold 5,000 Clovis Oncology, Inc. shares in Q4 2018, an estimated $147K.
Advent Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2016 and held it in 6 quarters.
Advent Capital Management's Clovis Oncology, Inc. position peaked at $1.76M in Q2 2017.
165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Advent Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.